Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
IBM heads into its October 21 Q3 earnings date with a cleaner week behind it but a trickier picture underneath: the stock is up 4.3% on the week to $230.78, yet short interest has risen 7.4% over the same period and the fundamental debate from July's guidance cut remains unresolved.
The week's most notable shift is in short positioning, and it runs against the grain of the price action. Short interest has climbed from roughly 21.3 million shares to 23.4 million shares, pushing the SI level to 2.5% of the free float. That is still a modest absolute figure, and the lending market is not the source of pressure: availability is extraordinarily loose at 7,659% of short interest, meaning there are roughly 77 shares available to borrow for every one already lent out, up sharply from 5,512% a week ago. The cost to borrow, at 0.40%, has actually eased 18% on the week. Taken together, the picture is of bears adding cautiously into a rally, not of a market bracing for a squeeze or pricing in serious downside. Options tell a similar story. The put/call ratio of 0.81 sits fractionally below its 20-day average of 0.83, slightly on the call-heavy side, consistent with no particular conviction in either direction ahead of the print. This is positioning that looks watchful rather than charged.
The Street is similarly non-committal. The consensus is a hold, with all eleven rated analysts clustered there, and the mean price target of $240.56 implies only modest upside to the current price. The most recent action this week was RBC Capital reiterating its Outperform rating with a $270 target, standing apart from the broader crowd. Truist initiated coverage last week at Hold with a $240 target, adding to the cautious middle. The real damage to targets came in July, when Morgan Stanley cut from $293 to $190 and Barclays trimmed from $288 to $262 after the pre-release. Since then targets have largely been stable, though Susquehanna nudged its Neutral target up to $235 in late August. The valuation picture is mixed: the price-to-earnings multiple has expanded about 4.5 points over the past month to 17.8x, reflecting the stock's partial recovery, but the P/B has contracted, and forward EPS momentum ranks in the bottom quartile of the universe. The dividend yield factor is a standout at the 99th percentile, the income base remains intact. On the bear side, management's July commentary pointed to a revenue growth cut to 4 to 5% for FY26, with TPS revenue estimated down 10 to 12% year-on-year in Q3, suggesting mainframe workload momentum may be softening despite stronger z17 shipments. The bull case leans on the recurring revenue base, roughly 80% of software revenue being recurring, and management's confidence in closing deferred deals.
One data point worth noting from the alt data layer: retail attention has picked up ahead of the print. Wikipedia views and ORTEX page activity for IBM are running about 1.9 standard deviations above the stock's own 90-day baseline, the highest reading visible in recent weeks. This is an attention signal, not a revenue indicator, but it does suggest the earnings event is drawing more scrutiny from retail observers than usual.
Among correlated peers, KD and ACN both had strong weeks, up 6.6% and 10.4% respectively, which provides some sector tailwind context for IBM's own 4.3% advance. UIS was the outlier, falling 4.8% on the week, a reminder that IT services names are not all moving in the same direction.
IBM's last two earnings prints produced a day-one drop of 1.8% and a flat move of 0.4%, but both resolved higher over five days, with the Q2 result gaining 7.6% across the following week. The Q3 print on October 21 is therefore less about whether the short base is large enough to matter and more about whether management provides any clarity on the guidance reset that has kept the stock range-bound since July.
See the live data behind this article on ORTEX.
Open IBM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.